- Risk of graft loss on once-daily versus twice-daily tacrolimus in kidney transplant patients: a meta-analysis
-
Kandarini Y, Mahadita GW, Widiana IGR, Paramita Ayu N
- KMID: 2535444
- Korean J Transplant.
- 2022 Nov;36(Supple 1):S227.
- doi: 10.4285/ATW2022.F-3635
Background: Tacrolimus has been used as immunosuppressant for various organ transplantation, including kidney. Recently, clinician is more interested in using once-daily tacrolimus compared to twice-daily due to higher adherence. One... -
- CITED
-
- Close
- SHARE
-
- Close
- The comparison of coefficient of variation among once-daily and twice-daily tacrolimus in kidney transplant patients: a meta-analysis
-
Mahadita GW, Widiana IGR, Kandarini Y
- KMID: 2535715
- Korean J Transplant.
- 2022 Nov;36(Supple 1):S199.
- doi: 10.4285/ATW2022.F-3334
Background: Kidney transplantation is the treatment of choice end stage renal disease. Tacrolimus often used as prophylaxis of organ rejection in patients receiving organ transplants. Maintaining tacrolimus trough levels is... -
- CITED
-
- Close
- SHARE
-
- Close
- Health technology assessment of kidney transplantation and hemodialysis for the treatment of end-stage kidney disease
-
Mahadita GW, Widiana IGR, H. Marbun MB, Ayu NP, Kandarini Y, Mahendra IBN, Pratiwi Duarsa RS, Putra IMR
- KMID: 2535268
- Korean J Transplant.
- 2022 Nov;36(Supple 1):S203.
- doi: 10.4285/ATW2022.F-3388
Background: Kidney transplantation is an expensive procedure, and it is an alternative treatment of end-stage renal disease other than dialysis. Cost-effectiveness and the cost-utility study was undertaken at Prof. Dr.... -
- CITED
-
- Close
- SHARE
-
- Close
